# Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

> **NCT00818961** · PHASE2 · TERMINATED · sponsor: **Northside Hospital, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** graft-versus-tumor induction therapy
- **BIOLOGICAL:** rituximab
- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **DRUG:** methotrexate
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic bone marrow transplantation

## Key facts

- **NCT ID:** NCT00818961
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2011-03
- **Final completion:** 2012-03
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** terminated early due to meeting end point with fewer patients than anticipated
- **Last updated:** 2013-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00818961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00818961, "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00818961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*